Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
A little about ISO 13485:2016lne-america.com/certification/iso-cer... Note that ISO 13485:2016 expands the profile of companies and organizations to which the standard can apply: Organizations involved in one or several stages of a Medical Device Lifecycle or a Supplier or other External Parties providing such organizations with products for example. Organizations involved in one or more stages of the medical device lifecyle Suppliers or External Parties who provide products to such Organizations Design and Development Production Storage Distribution Installation Servicing ... Raw materials Components Sub-assemblies Medical devices Sterilization services Calibration services Distribution services Maintenance services In addition, the ISO 13485 standard requires that the organization identifies its role(s) in connection with the regulatory requirements (e.g. Manufacturer, Representative, Importer and / or Distributor), and determines the applicable regulatory requirements depending on the role(s), then integrates the regulatory requirements in the QMS. A Quality Management System is neither meant to be a frozen in time nor is the company. The QMS is defined to help streamline and reinforce internal processes and procedures while carrying on with the changes and evolutions affecting the market. How is ISO 13485 recognized worldwide? ISO 13485 Standard pictoISO 13485 focuses on the harmonization of the Quality Management Systems in the framework of Medical Device regulatory requirements. It is not surprising to see that many jurisdictions recognize or even require that Medical Device manufacturers obtain ISO 13485 certification in order to access their market. A number of regulatory authorities have adopted the ISO 13485 certification standard as part of their own requirements to enable the sale of Medical Devices on their territory. The Medical Device Single Audit Program commonly referred to as MDSAP went a step further: it is built on the ISO 13485 principles and includes those principles as part of the audit criteria. ISO 13485 and the Medical Device Single Audit program (MDSAP) In the framework of the Medical Device Single Audit Program (MDSAP), organizations’ Quality Management System can be audited for potentially five different Medical Device markets. For companies selling or looking to expand their sales to one or to all of the countries involved in the MDSAP program (Australia, Brazil, Canada, USA, Japan), it is important to know that at a minimum, the requirements of ISO 13485 will be included in the auditing criteria along with only the applicable regulations of the authorities the company is concerned with. From what I can see, there are several examples of EU marking of various medical devices preceding ISO 13485 certification. So I don't think the EU registration was waiting on this certification. FL
Is it just me, or does the ImmunExpress Press Release seem to go out of its way not to mention Biocartis? My guess is that ImmunExpress (IE) carried just about all the water to provide quality control plans and documentation to win the approval. BCART has a lot of irons in the fire and cannot afford to dedicate an undo amount of effort in supporting just one product. If this is the case, the good news is that their partner stepped up to pull the documentation together and respond to questions. I may be reading between the lines too much but it is weird that the only mention of BCART is the license agreement between the companies. FL
Flatlander schreef op 27 februari 2020 14:50 :
Tyrck
Youth, is the exception. I think in 10 years you will be happy that you speculated as you did. I have no fear of BCART failing technically. Theranos was smoke and mirrors, BCART is not. Every journal review of Idylla that I have read is positive.
My only concerns are political and business execution related. By political I mean protectionist policies and regulatory approval processes. I think the political risks are mitigated by having large partners. In my opinion, the chief business execution risks are selling too soon (Verrelst has said in interviews he would not pursue a sale) and the loss of key personnel. The shareholder base of BCART is so fragmented that it will be next to impossible to orchestrate a takeover that is not broadly supported. I owned GHDX before the EXAS acquisition. All it took was the Baker Brothers deciding it was a good time to sell and GHDX was gone as an independent company. The personnel issue happens whenever key people leave. It can affect the ability to meet deadlines.
Best wishes for your Investing Future!
FL
Thanks FL :) I have time on my side so let's see where the wind will take us. Best of luck to you too. FYI, for energy, renewable energy and recycling I have Vestas Wind, Elia, Neste Oy, Veolia & Sif Holding on my watchlist. For 5G I think companies like NOK and ERIC can pose opportunities as well. I'm looking to enter in some new positions as well but I think I will wait a few more days...
Wat een slachting, straks zijn we even veel waard als de cash in kas.
Toch maar een order gezet op 4,72€. Dit is te zot voor woorden aan het worden.
Is dit nu werkelijk door het virus? Dit is toch wel een hele harde afslachting... @FL thanks for you time in this forum. I read daily your comments. You make me very enthousiastic and i'm also 25 so have the time on my side. But sometimes it looks like you have only "good" news. So that scares me also + it's my first 'crisis'. At the moment I try to keep calm. :D Gl 2 everyone. grtz Nestel
We zitten in een zware overdrijvingsfaze.Dat er een algemene kleine correctie op komst was stond in de sterren geschreven.Bij Biocartis kan je van een fel overdreven crach spreken.Min 60 procent tegenover vorig jaar.Totaal onterecht in mijn ogen. Super technologie,overal ter wereld meer verkopen,meer en meer deals met pharmabedrijven,uitbreiding van meerdere kankertest die in de pijplijn zitten. Eens veranderd die kudde van koers en zal het vechten worden voor de aandelen van Biocartis. En wie weet kan dat maandag al beginnen.
joe123 schreef op 28 februari 2020 11:38 :
We zitten in een zware overdrijvingsfaze.Dat er een algemene kleine correctie op komst was stond in de sterren geschreven.Bij Biocartis kan je van een fel overdreven crach spreken.Min 60 procent tegenover vorig jaar.Totaal onterecht in mijn ogen.
Super technologie,overal ter wereld meer verkopen,meer en meer deals met pharmabedrijven,uitbreiding van meerdere kankertest die in de pijplijn zitten.
Eens veranderd die kudde van koers en zal het vechten worden voor de aandelen van Biocartis.
En wie weet kan dat maandag al beginnen.
Proficiat aan de kopers van vandaag, zij zijn de winnaars van morgen!
Laup 4 schreef op 28 februari 2020 11:40 :
[...]
Proficiat aan de kopers van vandaag, zij zijn de winnaars van morgen!
Zolang het maar niet de verliezers van Maandag blijken te zijn. Biocartis is deels afhankelijk van onderdelen levering vanuit China. Wat voor exacte invloed dit heeft horen we pas aanstaande donderdag 5 Maart. Van een uitrol van het Idylla platform in China zal voorlopig ook geen sprake zijn en in Japan sluiten vanaf maandag ook lagere en middelbare scholen is ondertussen bekend gemaakt door de premier aldaar. Het is helaas nog te vroeg om terug te juichen bij Biocartis.
Nestel Most of my optimism is born out of the positive technical reviews of Idylla's ease of use, quick TAT and accuracy. I have said on occasion that history is littered with companies that had first mover advantage and a good product but failed to execute on the business side. You are right to push for balanced evaluation. I have cautioned that group think on discussion boards can be detrimental to your financial well being. Right now the biggest negative for BCART is the negative price momentum. But even in that there is a slight silver lining. During the past couple days the price action has been down hard on the open and middle of the day with a rally into the close. Usually, the smarter money tends to buy a close and not the open. I have largely focused discussions on what I believe to be the largest impediment to BCART. The registration issue must be resolved to open the intended markets throughout the world. When this begins to occur with the FDA, Japan and China it will unlock the ability to finally compete in the intended POC market. I expect this to start occurring outside the EU this year. I do have concerns about personnel. BCART is the kind of business that a few critical people can be very instrumental to achieving product-assay development and launches. I saw that Simone Marticke strategy adviser left BCART. She seemed impressive on a previous conference call. I can understand her reasoning for leaving. Getting paid to direct charitable fund distribution for the Gates Foundation would seem like an ideal job for a lot of people. BCART is continuing to roll out new products so the people that left do not appear to have had a detrimental effect. I do occasionally wonder if some of the delays in launches have been affected by some of the personnel changes. For the most part BCART is now getting hit by outside concerns that are outside their control. I've been thru several periods like this, while it is gut wrenching, the companies I have invested in have come through similar crisis periods and have prospered. Given BCARTs product, the market size, stated strategy and the near term launches I'm very optimistic. Regards FL
Heb je die eindsprint weer gezien, van 4,88 naar 4,97 euro? Bijna 30.000 stuks op enkele minuten. Dat zijn shorters die graag uw goedkope aandelen overnemen. Nu verkopen? aan deze bodemprijzen? en met nog 3 beursdagen tot de cijfers en doelstellingen???
Voila!bijgekocht(4,89).Biocartis is nu mijn grootste positie.Cijfers van donderdag moeten er bonk erop zijn,dat weet ik,dan nog hopen op een iets beter "beursklimaat"(?).Cash,zo'n 3€/a.Het resterende is maw. De waarde die de markt toekent aan bedrijf.Mijn inziens is dit een lachertje.
Ben nog te vlug geweest begin deze week, had beter gewacht dan was mijn gemiddelde beter, ik begrijp dat geshort niet, moet er me es in verdiepen, maar gokken op een dalende markt...
[quote alias=DRTVR id=12165986 date=202002282020] Ben nog te vlug geweest begin deze week, had beter gewacht dan was mijn gemiddelde beter, ik begrijp dat geshort niet, moet er me es in verdiepen, maar gokken op een dalende markt... [/quot Zeker nu niet meer mee beginnen drtvr Het is aan de longs nu.
joe123 schreef op 28 februari 2020 20:42 :
[quote alias=DRTVR id=12165986 date=202002282020]
Ben nog te vlug geweest begin deze week, had beter gewacht dan was mijn gemiddelde beter, ik begrijp dat geshort niet, moet er me es in verdiepen, maar gokken op een dalende markt...
[/quot
Zeker nu niet meer mee beginnen drtvr
Het is aan de longs nu.
Was de bedoeling niet, alleen curieus omdat er hier regelmatig over gesproken werd, dacht zeker dat aan 5,4 bodem bereikt was, durfde niet meer wachten, maar verkeerd gedacht. Hopelijk komt produktie niet in gedrang, en hebben ze genoeg voorraad om te kunnen blijven produceren.
Ik wacht toch nog even om me te versterken,ik denk dat het maandag in het algemeen een bloedrode dag zal worden op de beurs.
A little introspection. As we are seeing, this week BCART is not the type of stock that works well in this environment. Even companies with solid and growing earnings that pay a dividend are getting hit hard. BCART requires the belief that the point of care MDx market will be the wave of the future. That is why I have underscored the efforts of the industry giants Illumina, Fisher and Roche to launch new products to try to gain entrance into the POC MDx market. I have excepted that I have mistimed my establishing a position in BCART, but I will not compound this mistake by selling when prices are just above cash on the balance sheet levels. I have rationalized that a sale at this time would be stupid since the company is at the cusp of regulatory approvals that would allow them to finally sell into the intended POC diagnostic MDx market rather than the RUO market. I believe that Idylla will gain major traction when the POC providers realize that not only can they provide accurate results much quicker with Idylla but they are likely to turn Idylla into a profit center of their practice. If Idylla assays are reimbursed by insurers at anything close to the CLIA labs or NGS testing there will be considerable margin for the POC provider to profit from Idylla assays run at their facility. While there may be Coronavirus related setbacks/delays discussed on Thursday, it is simply the wrong time to sell. BCART is very likely a story for the next economic cycle assuming this downturn marks the end of a cycle. Unfortunately, that may mean that this virus initiates a global recession. BCART has the cash, products, partners, etc to make it through this cycle so they are better off than some their peers. The only thing they can control is their own execution, so I'll be listening for evidence that they continue to achieve milestones. FL
This should be required reading for BCART Shareholders! I had a version of this post where I highlighted numerous sections. I took a break for breakfast and when I posted it it gave an error and I lost the post. So this is the short version. FLwww.eacorp.com/wp-content/uploads/201... Key take aways include that the cancer genomics part of MDx is likely to be the fastest growing subsector. Testing is moving to the POC environment. Costs are coming down in most areas but Table 3 suggest constant pricing the past couple years due to push back from NGS firms. The insurance reimbursement rates are still about 100% higher than BCARTS costs. The entire conclusions section is a good summary of where things are headed.
Even though IVD manufacturer sales of FDA approved MDx tests for cancer are small today, this segment holds significant market potential because the clinical value of the tests is so high. For example, new companion diagnostic tests (CDx), which can command premium prices, are rapidly gaining adoption in clinical laboratories, a trend that is likely to continue given the numerous collaborations between pharma and diagnostic companies for CDx tests. Some of the key tests in this category include KRAS for colon cancer, EGFR for lung cancer, BRAF for melanoma and BCR-ABL for chronic myelogenous leukemia. Biocartis (Mechelen, Belgium) now offers a suite of these cancer tests on its sample-to-answer Idylla instrument platform. As for major market growth drivers in cancer testing, EAC sees the following: ? Emergence of new CDx based cancer tests over the next 3-5 years. ? Expanded use of existing cancer biomarkers for additional cancers (e.g. HER-2 in stomach cancer). ? Growing use of liquid biopsy tests for diagnosis, monitoring response to treatment or recurrence of cancer (e.g. blood test for EGFR gene in lung cancer). ? Continued growth in the use of NGS technologies for tumor profiling,
Flat great article and yet again the small Mechelen based company is named in a mayor revieuw of the IVD market .
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee